Finerenone

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Wednesday, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Type 1 Diabetes Market to Accelerate Substantially During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici

Retrieved on: 
Wednesday, November 15, 2023
Meal, Novo Nordisk, T1D, Prevalence, Therapy, Insulin, Weight loss, Abdominal pain, Eating, Disease, International Diabetes Federation, IDF, Fatigue, Autoantibody, Pancreas, Random glucose test, Finerenone, Urination, Health, Eli Lilly, Eli Lilly and Company, Diabetes, Gestational diabetes, Hunger, Hyperglycemia, Xerostomia, Type 1, Glycated hemoglobin, Glucose, LAS, Overalls, Vertex Pharmaceuticals, Type 2 diabetes, Hypoglycemia, Pharmaceutical industry, Dietary supplement, Bayer

LAS VEGAS, Nov. 15, 2023 /PRNewswire/ -- DelveInsight's Type 1 Diabetes Market Insights report includes a comprehensive understanding of current treatment practices, type 1 diabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • According to the International Diabetes Federation (IDF), Type 1 diabetes may affect anybody at any age, although it impacts children and adolescents the most commonly.
  • Over 1 million children and adolescents under the age of 20 have type 1 diabetes.
  • Diabetes is medically categorized into three primary types, with Type 1 diabetes, Type 2 diabetes, and gestational diabetes being the main classifications.
  • To know more about type 1 diabetes treatment, visit @ Type 1 Diabetes Treatment Drugs

Type 1 Diabetes Market to Accelerate Substantially During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici

Retrieved on: 
Wednesday, November 15, 2023
Meal, Novo Nordisk, T1D, Prevalence, Therapy, Insulin, Weight loss, Abdominal pain, Eating, Disease, International Diabetes Federation, IDF, Fatigue, Autoantibody, Pancreas, Random glucose test, Finerenone, Urination, Health, Eli Lilly, Eli Lilly and Company, Diabetes, Gestational diabetes, Hunger, Hyperglycemia, Xerostomia, Type 1, Glycated hemoglobin, Glucose, LAS, Overalls, Vertex Pharmaceuticals, Type 2 diabetes, Hypoglycemia, Pharmaceutical industry, Dietary supplement, Bayer

LAS VEGAS, Nov. 15, 2023 /PRNewswire/ -- DelveInsight's Type 1 Diabetes Market Insights report includes a comprehensive understanding of current treatment practices, type 1 diabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • According to the International Diabetes Federation (IDF), Type 1 diabetes may affect anybody at any age, although it impacts children and adolescents the most commonly.
  • Over 1 million children and adolescents under the age of 20 have type 1 diabetes.
  • Diabetes is medically categorized into three primary types, with Type 1 diabetes, Type 2 diabetes, and gestational diabetes being the main classifications.
  • To know more about type 1 diabetes treatment, visit @ Type 1 Diabetes Treatment Drugs

New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia® (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

Retrieved on: 
Saturday, November 4, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Enzyme inhibitor, Incidence, Hyperkalemia, EGFR, Observational study, MD, Kidney disease, Type 2 diabetes, UACR, Society, Chronic kidney disease, Disease, ASN, Risk, T2D, See, CKD, Safety, Hospital, Patient, Heart failure, Insulin, Pharmaceutical industry, Bayer, Finerenone

Bayer today announced new interim, real-world data on Kerendia® (finerenone) that complement the hyperkalemia and safety data in its pivotal trials.

Key Points: 
  • Bayer today announced new interim, real-world data on Kerendia® (finerenone) that complement the hyperkalemia and safety data in its pivotal trials.
  • The data was presented at the American Society of Nephrology’s (ASN) Kidney Week 2023.
  • Kerendia is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate dual cardiorenal risk reduction in adult patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
  • “Kerendia provides healthcare providers with a treatment option to slow chronic kidney disease progression and reduce cardiovascular risk in patients with CKD associated with T2D,” said Robert Perkins, MD, Vice President, Cardiovascular & Renal, Bayer.

New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

Retrieved on: 
Thursday, November 2, 2023
Research, FDA, Diabetes, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Plasma, Hyperkalemia, EGFR, Heart, Biomarker, Safety, Fibrosis, Kidney disease, Inflammation, Type 2 diabetes, Society, Chronic kidney disease, Phase, Central Executive Committee (PAP), ASN, Risk, T2D, Executive Committee, MOA, CKD, Hospital, Patient, Heart failure, Pharmaceutical industry, Bayer, Finerenone

2

Key Points: 
  • 2
    Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with CKD associated with T2D.3 The Kerendia label contains a Warning and Precaution that Kerendia can cause hyperkalemia.
  • The data from FIGARO-BM, an exploratory human biomarker study, provide findings which support the mechanism of action of Kerendia in blocking MR overactivation, thought to contribute to inflammation and fibrosis.
  • Left untreated, inflammation and fibrosis can lead to damage in the kidneys and heart.
  • 3
    “The biomarker findings from FIGARO-BM are an important moment for Bayer,” said Dr. Christian Rommel, Member of the Executive Committee of Bayer AG's Pharmaceutical Division and Head of Research and Development.

Bayer Expands Clinical Development Program Investigating Finerenone for Potential Treatment of Heart Failure

Retrieved on: 
Thursday, August 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, University, Heart failure, HF, Heart, Research, SOC, Finerenone, University of Colorado, Bayer, MD, Patient, Standard of care, Safety, Pharmaceutical industry

Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia® (finerenone) as a potential treatment for heart failure (HF) — with the initiation of three additional investigator-sponsored collaborative studies.1,2,3,4 Recruiting approximately 15,000 patients, MOONRAKER is expected to be one of the largest heart failure (HF) study programs to date.1,2,3,4

Key Points: 
  • Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia® (finerenone) as a potential treatment for heart failure (HF) — with the initiation of three additional investigator-sponsored collaborative studies.1,2,3,4 Recruiting approximately 15,000 patients, MOONRAKER is expected to be one of the largest heart failure (HF) study programs to date.1,2,3,4
    The three additional studies are sponsored by CPC Clinical Research, a non-profit academic research organization affiliated with University of Colorado, which is conducting the studies in collaboration with other academic research organizations.
  • The program is funded by Bayer.
  • “The newly added trials under MOONRAKER are designed to rigorously address common, important clinical scenarios for patients living with heart failure.
  • Simply put—more needs to be done, and quickly.

Bayer’s Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology

Retrieved on: 
Thursday, August 31, 2023
Health, Diabetes, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, MI, Heart failure, Chronic kidney disease, Hospital, Safety, HF, EGFR, Cardiovascular disease, Type 2 diabetes, SGLT2, Kidney disease, Bayer, Food and Drug Administration Amendments Act of 2007, MD, Risk, ESC, CKD, T2D, Food, Hyperkalemia, Dietary supplement, Pharmaceutical industry, Finerenone, Patient

The Kerendia label contains a Warning and Precaution that Kerendia can cause hyperkalemia.

Key Points: 
  • The Kerendia label contains a Warning and Precaution that Kerendia can cause hyperkalemia.
  • For more information, see “Important Safety Information” below.
  • “With the influx of new data, clinical guidance needs to be updated quickly.
  • Bayer is pleased that these new updates from ESC provide clear and timely treatment strategies health care professionals should consider when working to appropriately treat patients with type 2 diabetes and chronic kidney disease who are often medically complex.”

Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 Diabetes

Retrieved on: 
Thursday, June 22, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, TESA Collective, Hyperkalemia, Enzyme inhibitor, JDRF, ARB, Chronic kidney disease, Prevalence, Diabetes, Metabolism, T1D, FACP, Clinical trial, EGFR, Type 2 diabetes, Glomerular filtration rate, Kidney, Doctor of Philosophy, Finerenone, Washington University in St. Louis, Albuminuria, Kidney disease, Hypertension, Bayer, Patient, Division, Risk, RAS, Executive Committee, System, Single-use medical devices, UACR, MPH, CKD, Safety, T2D, News, Pharmaceutical industry, Medicine, MD, Endocrinology

Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D).

Key Points: 
  • Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D).
  • Finerenone is marketed as Kerendia® and approved for the treatment of adults with CKD associated with type 2 diabetes (T2D) in more than 70 countries worldwide, including the United States.
  • “Despite progress in risk reduction in type 2 diabetes, chronic kidney disease in type 1 diabetes remains understudied, leaving a huge unmet need for this population.
  • JDRF is committed to collaborating to help this critical trial succeed.”
    “For almost 30 years, there has been no new treatment approved to address the high risk of kidney disease progression in adults with chronic kidney disease and type 1 diabetes.

Substantial Changes in Management of Patients with Chronic Kidney Disease as New Treatment Options Such as Bayer's Kerendia and SGLT2 Inhibitors Gain Traction in US and EU Markets

Retrieved on: 
Friday, January 20, 2023
RealTime, HIV disease progression rates, UK, Bayer, AstraZeneca, DKD, ARB, MRAS, MRA, PCP, Spironolactone, Kidney, CKD, Health, ACE, Nephrology, Eplerenone, Physician, SGLT2, NASA RealWorld-InWorld Engineering Design Challenge, Novo Nordisk, Patient, Prescription, Diabetic nephropathy, Cowra breakout, Research, Diabetes, Empagliflozin, Pharmaceutical industry, Finerenone, EU

EXTON, Pa., Jan. 20, 2023 /PRNewswire/ -- With SGLT2 inhibitors increasingly becoming the standard of care for diabetic and non-diabetic CKD patients, the broader CKD treatment has begun to change notably.

Key Points: 
  • Of note, while use of mineralocorticoid antagonists (MRAs) – including the newer option Kerendia (Bayer) – has increased over the past year, nephrologists indicate SGLT2 inhibitors remain their most likely first step for patients.
  • Since the approval of Kerendia in July 2021, the use of MRA products overall (inclusive of Kerendia, spironolactone, and eplerenone) in CKD non-dialysis patients has also grown substantially.
  • This research will build off the inaugural research in 2022 of 1,282 patients collected in collaboration with 263 European nephrologists.
  • Results of Spherix's second annual EU chart audit will publish later this spring with notable changes likely to appear.